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in hard-back form makes it expensive for the
information it contains.
D. PEARSON
Chemotherapy of Solid Tumours-
Report of a WHO Expert Committee.
Technical Report Series 605. (1977).
106 pp. Sw. fr. 10.00 net. U.S.$4.00 net.
This book is one of a series of reports pro-
duced by WHO Expert Committees. The
members are eminent chemotherapists chosen
fromaround the world; the excellence oftheir
knowledge is reflected in both the compre-
hensiveness and relatively up-to-date content.
However, the reviewer questions the value
of such books and wonders to which readers
it is directed. The volume is not large enough
to be a text book on chemotherapy.
It is perhaps to be regarded as an intro-
duction to chemotherapy for those who are
not practising it. There appears to have been
a regrettable lack of radiotherapeutic advice
in the preparation ofthis document, resulting
in one or two lapses inthetext, asindiscussing
Methotrexate and Razoxane as radiosensiti-
sers.
The report is well written.
N. M. BLEEHEN
Pathology of Tumours in Laboratory
Animals Vol. 1.-Tumours of the Rat,
Part 2. Ed. V. S. TURUSOV (1976). Lyon:
International Agency for Research on
Cancer. 319 PP. U.S.$35.00 net.
This part of Tumours of the Rat includes
chapters on the respiratory tract, liver,
urogenital system, pituitary, thyroid, adrenal,
central and peripheral nervous systems and
the heart. As with Part 1, the aim is to
establish a standardized terminology in the
field of tumours in laboratory rats. This
volume will go some way towards this, but
there are obvious differences in nomenclature
depending on the source of material. In most
chapters there is a brief description of the
normal structure of the organ. As a result of
their brevity these are of limited use, and in
some instances omit important features or
may be misleading. On nomenclature, these
volumes are internally inconsistent. For
example, a "benign hepatoma" is described
in the liver, while in the 1968 IARC publica-
tion No. 1 on Liver Cancer there was a
recommendation that this term should not be
used. In the present volume it is being used
to designate a "benign neoplasm" while
there is an editor's note that the term
"hepatoma" in the volume on tumours of the
mouse is used for both benign and malignant
liver tumours. This is just one example of
inconsistency. Many of the chapters give
excellent descriptions and illustrations of the
tumours, but others are less helpful due to
the brevity of the description, as in the
nervous system, or in the highly specialized
nature ofthe information, as in the pituitary.
For a volume such as this to be successful it is
important that the quality of illustration is
high. There has been considerable improve-
ment over Part 1, but much remains to be
done. For example, in the chapter ontumours
of the vagina the selected photographs are
often too small to be ofuse, and following the
excellent discussion of the thyroid, many of
the illustrations are of poor focus. A good
feature of this volume in general is that the
authors discuss the problems of differential
diagnosis and in particular often refer to the
problems in distinguishing hyperplasias from
neoplasias. This book can be recommended
as a most useful addition to the information
which is available on the tumours of labora-
tory animals.
W. H. BUTLER
Adjuvant Therapy of Cancer. Ed. S. E.
SALMON and S. E. JONES (1977). Amster-
dam: Elsevier/North-Holland. 646 pp.
U.S.$53.95 net.
This is an excellent publication, dealing
with a subject that is currently occupying
the minds of very many clinical oncologists.
Chemotherapy has passed through several
phases, notably those ofthe single agent and,
later, of the proliferation ofever more exotic
combinations for the treatment of advanced
malignancy. Adjuvant chemotherapy is the
phase of the moment. It is likely (though
even this is being questioned) that chemo-
therapy is most effective when there is a
small body-burden of tumour (i.e. micro-
metastases) so it is very reasonable to offer
adjuvant treatment to high-risk patients in
this category. This book contains many papers
often of a very high standard, dealing with
clinical applications and results, but also